NCT01442545View on ClinicalTrials.gov

A Study to Investigate How JNJ-39758979 May Affect the Plasma Levels of Methotrexate in Rheumatoid Arthritis Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2011

Study Completion Date

December 31, 2011

Conditions

Rheumatoid Arthritis

Interventions

DRUG

JNJ-39758979 / MTX

Day 1: MTX: Route=oral use, single dose of participant's weekly MTX dose; Days 3-15: MTX: Route=oral use, single dose of participant's weekly MTX dose and JNJ 39758979: Type=exact, unit=mg, number=300, form=tablet, route=oral use, administered daily.

Trial Locations (5)

Unknown

Daytona Beach

Duncansville

Dallas

Berlin

Munich

All Listed Sponsors

lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT01442545 - A Study to Investigate How JNJ-39758979 May Affect the Plasma Levels of Methotrexate in Rheumatoid Arthritis Participants | Biotech Hunter | Biotech Hunter